PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12452328

A decrease in the amount and function of the stimulatory GTP-binding protein in the small resistance arteries of spontaneously hypertensive rats.

Eishin Shimizu·Mitsumasa Ohyanagi·Motomaru Masutani·Tadaaki Iwasaki
View original source ↗Export metadata ↓

Abstract

We investigated the concentration of stimulatory GTP-binding protein (Gs protein) in the peripheral resistance arteries of spontaneously hypertensive rats (SHR), normotensive Wistar-Kyoto rats (WKY), and renovascular hypertensive rats (RHR). Changes in the function of Gs protein in SHR and WKY were also investigated by microcannulation techniques. The localization and abundance of Gs protein were determined immunohistochemically in 4-, 10- and 20-week-old SHR and age-matched WKY (control), as well as in RHR. Sections of the cremaster artery were stained with polyclonal antibodies to Gs protein. The concentration of Gs protein-like immunoreactivity in the cremaster artery was significantly lower in SHR at 4, 10, and 20 weeks of age, relative to that in age-matched WKY. In contrast, no significant differences were detected in the abundance of Gs between RHR and control rats. The dilatory response by isoproterenol in the presence of beta1-adrenoceptor blocker was lower in 4- and 10-week-old SHR than in age-matched WKY. The dilatory response by cholera toxin was also lower in SHR than in WKY for these two age groups. These results indicated that the amount and function of Gs protein in the peripheral resistance vessels in SHR was reduced. Since this change occurred before the onset of hypertension and no changes were seen in the secondary hypertensive rats, this change was not a secondary change due to hypertension. The impaired receptor-Gs protein-mediated signal transduction in the peripheral resistance arteries may be one of the possible mechanisms responsible for the pathogenesis of hypertension in SHR.

Explore related subjects

Adrenergic beta-AgonistsAnimalsArteriesBlood PressureGTP-Binding Protein alpha Subunits, GsHypertensionIsoproterenolMuscle, Smooth, VascularNitroprussideRatsRats, Inbred SHRRats, Inbred WKYVascular ResistanceVasodilationVasodilator AgentsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eishin Shimizu, Mitsumasa Ohyanagi, Motomaru Masutani, Tadaaki Iwasaki. 2002. A decrease in the amount and function of the stimulatory GTP-binding protein in the small resistance arteries of spontaneously hypertensive rats.. https://doi.org/10.1291/hypres.25.743

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms.

Treatment with lipopolysaccharide (LPS) for 72 h was shown to dose-dependently increase nitric oxide production from 6-day-old retinal cultures. Cell death, as determined by lactate dehydrogenase (LDH) release and an increase in neuronal labelling for TUNEL, was elevated concurrently. During treatment there was an increase of both inducible nitric oxide synthase and glial fibrillary acidic protein labelling in glial cells and a reduction in the number of gamma-aminobutyric acid-positive neurones. The NOS inhibitors, N-nitro-L-arginine methyl ester, dexamethasone and indomethacin potently inhibited both nitric oxide stimulation and cell death caused by LPS. In this study, the beta(2)- (ICI-18551), beta(1)- (betaxolol) and mixed beta(1)/beta(2)- (timolol, metipranolol) adrenergic receptor antagonists were all shown to attenuate LPS-induced LDH release from these cultures, but to have no effect on LPS-stimulated nitric oxide production. This effect was mimicked by the calcium channel blocker, nifedipine. Interestingly, the beta-adrenergic receptor agonists, salbutamol, arterenol and isoproterenol were also able to attenuate cell death caused by LPS. Moreover, these compounds also inhibited LPS-stimulated nitric oxide release. These studies suggest that LPS stimulates nitric oxide release from cultured retinal glial cells and that this process leads to neurone death. beta-adrenergic receptor agonists prevent the effects of LPS by inhibiting the stimulation of nitric oxide production. The data also suggest that beta-adrenergic receptor antagonists can attenuate LPS-induced death of neurones, but that these compounds act in a manner that is neurone-dependent, is mimicked by blockade of calcium channels and is independent of the stimulation of nitric oxide release.

Adrenergic beta-Agonists↗
PubMed2003

Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

It is becoming increasingly clear that signaling via G protein-coupled receptors is a diverse phenomenon involving receptor interaction with a variety of signaling partners. Despite this diversity, receptor ligands are commonly classified only according to their ability to modify G protein-dependent signaling. Here we show that beta2AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1/2 thus behaving as dual efficacy ligands. ERK1/2 activation by dual efficacy ligands was not affected by ADP-ribosylation of Galphai and could be observed in S49-cyc- cells lacking Galphas indicating that, unlike the conventional agonist isoproterenol, these drugs induce ERK1/2 activation in a Gs/i-independent manner. In contrast, this activation was inhibited by a dominant negative mutant of beta-arrestin and was abolished in mouse embryonic fibroblasts lacking beta-arrestin 1 and 2. The role of beta-arrestin was further confirmed by showing that transfection of beta-arrestin 2 in these knockout cells restored ICI118551 promoted ERK1/2 activation. ICI118551 and propranolol also promoted beta-arrestin recruitment to the receptor. Taken together, these observations suggest that beta-arrestin recruitment is not an exclusive property of agonists, and that ligands classically classified as inverse agonists rely exclusively on beta-arrestin for their positive signaling activity. This phenomenon is not unique to beta2-adrenergic ligands because SR121463B, an inverse agonist on the V2 vasopressin receptor-stimulated adenylyl cyclase, recruited beta-arrestin and stimulated ERK1/2. These results point to a multistate model of receptor activation in which ligand-specific conformations are capable of differentially activating distinct signaling partners.

Adrenergic beta-Agonists↗
PubMed2003

H89, an inhibitor of protein kinase A (PKA), stimulates Na+ transport by translocating an epithelial Na+ channel (ENaC) in fetal rat alveolar type II epithelium.

The present study was performed to clarify the effect of H89, an inhibitor of cAMP-activated protein kinase (protein kinase A; PKA), on Na(+) absorption in fetal rat alveolar type II epithelium. H89 stimulated the Na(+) absorption by increasing the open probability (Po) and number of a nonselective cation (NSC) channel composed of four alpha subunits of epithelial Na(+) channel (ENaC). Brefeldin A (BFA), an inhibitor of intracellular protein translocation, blocked the stimulatory action of H89 on the Na(+) absorption by interrupting the action of H89 on the Po and number of the NSC channel. H85, an inactive form of H89, showed an effect similar to H89, suggesting that H89 does not show its effect by inhibiting PKA, but acts on the channel depending the structure. These observations indicate that: (1) the H89 induced increase in number of the channel at the apical membrane is due to translocation of alpha subunit of ENaC to the apical membrane, (2) the elevation of Po of the channel is mediated through translocation of a protein activating alpha subunit of ENaC, and (3) the effect of H89 is dependent on its structure without any relation to PKA.

Adrenergic beta-Agonists↗